Faron Pharmaceuticals raises £10 million

Faron Pharmaceuticals Oy of Finland has raised £10 million gross on the AIM market in London in order to help finance a Phase 3 trial of its agent for acute respiratory distress syndrome Traumakine, a recombinant human interferon beta-1a product.